Purchase this article with an account.
I. J. Suner, R. Varma, N. M. Bressler, P. P. Lee, C. Dolan, J. Ward, S. Colman, R. Rubio; Improvements in Reading Speed After 6 Months of Ranibizumab Treatment in Bravo and Cruise. Invest. Ophthalmol. Vis. Sci. 2010;51(13):945.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To examine the efficacy of ranibizumab (Lucentis®) on measured reading speed using a reading speed test through 6 months in subjects with macular edema following retinal vein occlusion (RVO).
Two multicenter, double-masked, phase III trials in which participants with macular edema following branch RVO (BRAVO) or central RVO (CRUISE) were randomized 1:1:1 to monthly sham, 0.3-mg or 0.5-mg ranibizumab for 6 months. Reading speed in the study eye was measured using a test designed by the Macular Photocoagulation Study group through collaboration with the Lighthouse in New York. The number of correctly read words per minute is reported. The test requires a maximum 6th grade reading level. It does not take into account literacy or cognitive state. The reading speed test was administered at 0, 1, 3, and 6 months.
At 6 months, ranibizumab-treated patients had greater mean gains in reading speed in study eyes than patients with sham-treated study eyes (Figure).
In BRAVO and CRUISE, patients with macular edema following RVO subsequently treated monthly with ranibizumab had, on average, greater improvements in reading speed in study eyes, a direct patient performance assessment of reading ability and visual function, through 6 months compared with sham treatment.
www.clinicaltrials.gov NCT00486018, NCT00485836
This PDF is available to Subscribers Only